NMPA Publishes 110th Batch of Chemical Generic Drug Reference Listed Drug Catalog – 28 New Specifications Added
Policy / Regulatory

NMPA Publishes 110th Batch of Chemical Generic Drug Reference Listed Drug Catalog – 28 New Specifications Added

The National Medical Products Administration (NMPA) has released the 110th batch of the Catalog of Reference Listed Drugs (RLD) for Chemical Generic Drugs, adding 28 new drug specifications and providing…

FDA Approves AbbVie's Tavapadon as Juvmo for Parkinson's Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfoli
CompanyDrug

FDA Approves AbbVie’s Tavapadon as Juvmo for Parkinson’s Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfolio

Jenscare's JensClip Wins NMPA Registration Approval – Self‑Locking Transcatheter Mitral Valve Repair Clip Enters the Chinese Market
CompanyMedical Device

Jenscare’s JensClip Wins NMPA Registration Approval – Self‑Locking Transcatheter Mitral Valve Repair Clip Enters the Chinese Market

Novo Nordisk's NovoGlic Wins Expanded NMPA Approval – First Weekly Insulin Icodec/Semaglutide Combination Broadens Type 2 Diabetes Care in China
CompanyDrug

Novo Nordisk’s NovoGlic Wins Expanded NMPA Approval – First Weekly Insulin Icodec/Semaglutide Combination Broadens Type 2 Diabetes Care in China

BMS Secures Conditional NMPA Approval for Zenbexus (Iberdomide) – World's First Oral CELMoD Agent Wins China Landmark in Relapsed Multiple Myeloma
CompanyDrug

BMS Secures Conditional NMPA Approval for Zenbexus (Iberdomide) – World’s First Oral CELMoD Agent Wins China Landmark in Relapsed Multiple Myeloma

Merck's Subcutaneous Pembrolizumab Approved by China's NMPA Across 19 Solid Tumor Indications – First and Only Subcutaneous PD‑1 Inhibitor in China
CompanyDrug

Merck’s Subcutaneous Pembrolizumab Approved by China’s NMPA Across 19 Solid Tumor Indications – First and Only Subcutaneous PD‑1 Inhibitor in China

EyePoint's DURAVYU Misses Primary Endpoint in Phase III LUCIA Trial for Wet AMD – Non‑Inferiority vs. Aflibercept Not Achieved; Key Secondary Endpoints Met
CompanyDrug

EyePoint’s DURAVYU Misses Primary Endpoint in Phase III LUCIA Trial for Wet AMD – Non‑Inferiority vs. Aflibercept Not Achieved; Key Secondary Endpoints Met

Eli Lilly's Omvoh Delivers First One‑Year Phase 3 Readout in Pediatric Ulcerative Colitis – 50 % Clinical Remission at Week 52 in SHINE‑2
CompanyDrug

Eli Lilly’s Omvoh Delivers First One‑Year Phase 3 Readout in Pediatric Ulcerative Colitis – 50 % Clinical Remission at Week 52 in SHINE‑2

AbbVie's Dual‑Targeting ABBV‑466 Outperforms Both Monotherapies in Crohn's Disease – Higher Endoscopic Remission Rates at Week 12 in TARGET‑CD Study
CompanyDrug

AbbVie’s Dual‑Targeting ABBV‑466 Outperforms Both Monotherapies in Crohn’s Disease – Higher Endoscopic Remission Rates at Week 12 in TARGET‑CD Study

Mabwell to Present Phase II Data for Nectin‑4 ADC 9MW2821 at ESMO 2026 – 30.0% ORR in Post‑TOP1i‑ADC Triple‑Negative Breast Cancer, Headlining Four Phase III Programs
CompanyDrug

Mabwell to Present Phase II Data for Nectin‑4 ADC 9MW2821 at ESMO 2026 – 30.0% ORR in Post‑TOP1i‑ADC Triple‑Negative Breast Cancer, Headlining Four Phase III Programs

Johnson & Johnson Posts Q3 2026 Revenue of USD 25.4 Billion, Raises Full‑Year Guidance – Innovative Medicine Drives 6.0% Operational Growth

Johnson & Johnson Posts Q3 2026 Revenue of USD 25.4 Billion, Raises Full‑Year Guidance – Innovative Medicine Drives 6.0% Operational Growth

Johnson & Johnson (NYSE: JNJ) reported third‑quarter 2026 revenue of USD 25.4 billion, up 5.9% year on year, led by its Innovative Medicine business, and raised its full‑year sales and adjusted earnings guidance. Operational growth, excluding currency effects, reached 6.0%,…

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

METiS TechBio Partners with Eli Lilly on AI‑Driven Lipid Nanoparticle Delivery – Up to USD 1.1 Billion in Milestones for Tissue‑Specific LNP Discovery
CompanyDeals

METiS TechBio Partners with Eli Lilly on AI‑Driven Lipid Nanoparticle Delivery – Up to USD 1.1 Billion in Milestones for Tissue‑Specific LNP Discovery

Sanofi Breaks Ground on Next‑Generation Insulin Manufacturing Facility at Frankfurt BioCampus – Full API Production Planned for 2032
Company

Sanofi Breaks Ground on Next‑Generation Insulin Manufacturing Facility at Frankfurt BioCampus – Full API Production Planned for 2032

Hansoh Pharma Strikes Second ADC Licensing Deal with Roche – USD 400 Million Upfront, Over USD 15 Billion in Potential Milestones
CompanyDeals

Hansoh Pharma Strikes Second ADC Licensing Deal with Roche – USD 400 Million Upfront, Over USD 15 Billion in Potential Milestones

Insilico Medicine Earns Milestone Payment from Servier – First Oncology Program Hits Early‑Stage Drug Discovery Mark on Pharma.AI Platform
CompanyDeals

Insilico Medicine Earns Milestone Payment from Servier – First Oncology Program Hits Early‑Stage Drug Discovery Mark on Pharma.AI Platform

Merck KGaA to Acquire Silence Therapeutics for USD 1.1 Billion Enterprise Value – Gaining Potential Best‑in‑Class siRNA Asset Divesiran
CompanyDeals

Merck KGaA to Acquire Silence Therapeutics for USD 1.1 Billion Enterprise Value – Gaining Potential Best‑in‑Class siRNA Asset Divesiran

Where biopharma's biggest deals take shape!

Your front-row seat to the deals reshaping the pharmaceutical landscape — mergers and acquisitions, licensing agreements, venture investments, and strategic partnerships. We track every major transaction, from blockbuster M&As to early-stage funding rounds, breaking down what each deal means for the companies, the pipeline, and the market.
M&A and Licensing
Porton Advanced Solutions Partners with Hangzhou Aisijia Biotech on Diabetes Cell Therapy – CDMO to Provide Process Development, GMP Manufacturing and China IND Filing Support for Autologous Pancreatic Progenitor Cell Program
CompanyDeals

Porton Advanced Solutions Partners with Hangzhou Aisijia Biotech on Diabetes Cell Therapy – CDMO to Provide Process Development, GMP Manufacturing and China IND Filing Support for Autologous Pancreatic Progenitor Cell Program

Porton Advanced Solutions Ltd. ("Porton Advanced Solutions") and Hangzhou Aisijia Biotech Co., Ltd. ("Aisijia Biotech") announced a strategic collaboration centered on the new drug clinical trial (IND) application in China…

Ascentage Pharma Signs Strategic Collaboration with Suzhou University and Its First Affiliated Hospital – Tripartite Partnership Targets Hematologic Oncology Innovation
CompanyDeals

Ascentage Pharma Signs Strategic Collaboration with Suzhou University and Its First Affiliated Hospital – Tripartite Partnership Targets Hematologic Oncology Innovation

Qingfeng Pharmaceutical Signs Five‑Year Strategic Collaboration with China Association Against Epilepsy – Advancing Discipline Development, Talent Cultivation and Patient Assistance
CompanyDeals

Qingfeng Pharmaceutical Signs Five‑Year Strategic Collaboration with China Association Against Epilepsy – Advancing Discipline Development, Talent Cultivation and Patient Assistance

Biohaven Licenses MoDE Pan‑IgG Degrader Portfolio to Ono Pharmaceutical in Asia – Up to USD 100 Million in Near‑Term Payments for BHV‑1300 Franchise
CompanyDeals

Biohaven Licenses MoDE Pan‑IgG Degrader Portfolio to Ono Pharmaceutical in Asia – Up to USD 100 Million in Near‑Term Payments for BHV‑1300 Franchise

Mirxes Partners with Thailand's National Cancer Institute on Blood‑Based Colorectal Cancer Screening – 2,000‑Subject Prospective Triage Study Backs "Cancer Moonshot 2056"
CompanyDeals

Mirxes Partners with Thailand’s National Cancer Institute on Blood‑Based Colorectal Cancer Screening – 2,000‑Subject Prospective Triage Study Backs “Cancer Moonshot 2056”

- Advertisement -
Baheal Pharmaceutical Completes ~USD 11 Million Investment in Zap Medical – Subsidiary Baheal Health Exercises Warrants for Series E‑1 Preferred Shares
CompanyDeals

Baheal Pharmaceutical Completes ~USD 11 Million Investment in Zap Medical – Subsidiary Baheal Health Exercises Warrants for Series E‑1 Preferred Shares

Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1
CompanyDeals

Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech's CNS and Brain‑Penetrant Drug Pipeline
CompanyDeals

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech’s CNS and Brain‑Penetrant Drug Pipeline

Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances "Closed‑Loop Nerve Bundle Modulation" Platform
CompanyDeals

Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances “Closed‑Loop Nerve Bundle Modulation” Platform

China's CDE Launches "Pioneer Plan" Pilot to Advance New Approach Methodologies (NAMs) in Non‑Clinical Drug Evaluation – Aiming to Reduce, Refine, and Replace Animal Testing
Policy / Regulatory

China’s CDE Launches “Pioneer Plan” Pilot to Advance New Approach Methodologies (NAMs) in Non‑Clinical Drug Evaluation – Aiming to Reduce, Refine, and Replace Animal Testing

The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) issued the Pilot Plan for Promoting the Research and Application of New Approach Methodologies (the "Pioneer Plan"),…

NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs
Policy / Regulatory

NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs

MOFCOM and MOST Open Consultation on Revised Technology Export Catalogue – 40 Technologies Across AI, Biopharmaceuticals and Photovoltaics Proposed for Addition
Policy / Regulatory

MOFCOM and MOST Open Consultation on Revised Technology Export Catalogue – 40 Technologies Across AI, Biopharmaceuticals and Photovoltaics Proposed for Addition

CDE Opens Public Comment on 111th Batch Draft of Reference Preparations Catalogue – 25 New Specifications Proposed for Chemical Generic Drugs
Policy / Regulatory

CDE Opens Public Comment on 111th Batch Draft of Reference Preparations Catalogue – 25 New Specifications Proposed for Chemical Generic Drugs

More News

EMA's CHMP Backs Flexible Dosing for Regeneron's Libtayo – Every‑Six‑Week 700 mg Regimen and Shortened Infusion Options Across All Approved PD‑1 Indications
CompanyDrug

EMA’s CHMP Backs Flexible Dosing for Regeneron’s Libtayo – Every‑Six‑Week 700 mg Regimen and Shortened Infusion Options Across All Approved PD‑1 Indications

EMA's CHMP Backs Indication Extension for Johnson & Johnson's TALVEY – Talquetamab Combination Moves Toward Earlier‑Line Relapsed/Refractory Multiple Myeloma
CompanyDrug

EMA’s CHMP Backs Indication Extension for Johnson & Johnson’s TALVEY – Talquetamab Combination Moves Toward Earlier‑Line Relapsed/Refractory Multiple Myeloma

FDA Approves Roche's Enspryng for Thyroid Eye Disease – Satralizumab Becomes First and Only At‑Home Subcutaneous TED Treatment
CompanyDrug

FDA Approves Roche’s Enspryng for Thyroid Eye Disease – Satralizumab Becomes First and Only At‑Home Subcutaneous TED Treatment

FDA Approves Viatris's RYZUMVI for Presbyopia – Phentolamine Ophthalmic Solution 0.75% Adds Age‑Related Vision Indication to Existing Mydriasis Label
CompanyDrug

FDA Approves Viatris’s RYZUMVI for Presbyopia – Phentolamine Ophthalmic Solution 0.75% Adds Age‑Related Vision Indication to Existing Mydriasis Label

GSK Reports First Global Data for B7‑H3 ADC Risvutatug Rezetecan – 61% Confirmed ORR at 8 mg/kg in Relapsed ES‑SCLC Phase Ib
CompanyDrug

GSK Reports First Global Data for B7‑H3 ADC Risvutatug Rezetecan – 61% Confirmed ORR at 8 mg/kg in Relapsed ES‑SCLC Phase Ib

Huadong Medicine's Doer Bio Wins NMPA Clearance to Trial DR30206 – Tri‑Target PD‑L1/VEGF/TGF‑β Fusion Protein Advances into Stage III NSCLC Consolidation Therapy
CompanyDrug

Huadong Medicine’s Doer Bio Wins NMPA Clearance to Trial DR30206 – Tri‑Target PD‑L1/VEGF/TGF‑β Fusion Protein Advances into Stage III NSCLC Consolidation Therapy

Bio-Link Capital Completes Strategic Investment in TYK Medicines – Doubling Down on Bispecific, Trispecific and ADC Antibody Platforms
CompanyDeals

Bio-Link Capital Completes Strategic Investment in TYK Medicines – Doubling Down on Bispecific, Trispecific and ADC Antibody Platforms

Brii Biosciences Launches BRiSC Bispecific siRNA Platform – Dual‑Target RNAi Engine to Advance Next‑Generation RNA Therapeutics in Prevalent Diseases
CompanyR&D

Brii Biosciences Launches BRiSC Bispecific siRNA Platform – Dual‑Target RNAi Engine to Advance Next‑Generation RNA Therapeutics in Prevalent Diseases

Show More